| 5.372 -0.378 (-6.57%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.32 | 1-year : | 9.72 |
| Resists | First : | 7.13 | Second : | 8.32 |
| Pivot price | 5.2  |
|||
| Supports | First : | 4.8 |
Second : | 3.35 |
| MAs | MA(5) : | 5.23 |
MA(20) : | 4.88 |
| MA(100) : | 4.5 |
MA(250) : | 5.04 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 47.8 |
D(3) : | 47.2 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 7.13 | Low : | 3.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PLUR ] has closed below upper band by 42.9%. Bollinger Bands are 127.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.77 - 5.8 | 5.8 - 5.82 |
| Low: | 5.2 - 5.23 | 5.23 - 5.25 |
| Close: | 5.32 - 5.37 | 5.37 - 5.41 |
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Tue, 29 Apr 2025
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com
Mon, 28 Apr 2025
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan
Mon, 28 Apr 2025
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - Yahoo Finance
Mon, 21 Apr 2025
DarioHealth Taps Israeli CFO Excellence Award Winner to Lead Next Growth Phase - Stock Titan
Thu, 17 Apr 2025
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com
Tue, 08 Apr 2025
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -12 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 7e+006 (%) |
| Held by Institutions | 3.43e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 474000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.69 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 679.4 % |
| Return on Equity (ttm) | -37.5 % |
| Qtrly Rev. Growth | 102.5 % |
| Gross Profit (p.s.) | -8.29 |
| Sales Per Share | -126.43 |
| EBITDA (p.s.) | 197546 |
| Qtrly Earnings Growth | -2.147e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.46 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0 |
| Dividend | 8530 |
| Forward Dividend | 18050 |
| Dividend Yield | 158786% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|